MetaCap

Amylyx Pharmaceuticals (AMLX) vs Disc Medicine (IRON)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amylyx Pharmaceuticals (AMLX) has outperformed Disc Medicine (IRON) over the past year, gaining 77.4% versus a loss of 18.9%. Disc Medicine is the larger company by market cap ($3.42 billion vs $3.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMLX+77.37%IRON-18.86%
+181%+65%-50%
Nov 21, 20251 yearNov 20, 2026
AMLX+44.00%IRON-1.78%
+137%+18%-102%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMLX versus IRON key metrics
MetricAMLXIRON
Share price$26.02$75.14
Market cap$3.35B$3.42B
1-day change-0.69%-1.27%
YTD return+115.40%-5.38%
1-year return+77.37%-18.86%
5-year return—-14.22%
EPS (TTM)$-1.43$-6.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-144.74M$-212.18M
52-week high$41.14$99.50
52-week low$10.83$40.00
Distance from 52-week high-36.75%-24.48%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+65.26%+69.94%
Average volume1.53M951.56K
Shares outstanding128.56M45.54M
Employees136173
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMLX has outperformed IRON by 96.2 percentage points over the past year.

About Amylyx Pharmaceuticals

AMLX stock →

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.

Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees

About Disc Medicine

IRON stock →

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees

AMLX vs IRON FAQ

Which is bigger, Amylyx Pharmaceuticals or Disc Medicine?

Disc Medicine (IRON) is larger, with a market capitalization of $3.42B compared with $3.35B for Amylyx Pharmaceuticals (AMLX).

Which stock has performed better over the past year, AMLX or IRON?

AMLX returned +77.37% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.

Are Amylyx Pharmaceuticals and Disc Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons